Christian GAIDDON

DR2 CNRS – Responsable équipe 2

Profil Linkedin

(+33) 06 83 52 53 56




Liste des publications :


Beck, M., Baranger, M., Moufok-Sadoun, A., Bersuder, E., Hinkel, I., Mellitzer, G., Martin, E., Marisa, L., Duluc, I., de Reynies, A., Gaiddon, C., Freund, J.-N., & Gross, I. (2020). The atypical cadherin MUCDHL antagonizes colon cancer formation and inhibits oncogenic signaling through multiple mechanisms. Oncogene.
Voisinet, M., Venkatasamy, A., Alratrout, H., Delhorme, J.-B., Brigand, C., Rohr, S., Gaiddon, C., & Romain, B. (2020). How to Prevent Sarcopenia Occurrence during Neoadjuvant Chemotherapy for Oesogastric Adenocarcinoma? Nutrition and Cancer, 1–7.
Solís-Ruiz, J. A., Barthe, A., Riegel, G., Saavedra-Díaz, R. O., Gaiddon, C., & Le Lagadec, R. (2020). Light activation of cyclometalated ruthenium complexes drives towards caspase 3 dependent apoptosis in gastric cancer cells. Journal of Inorganic Biochemistry, 208, 111080.
Licona, C., Delhorme, J.-B., Riegel, G., Vidimar, V., Cerón-Camacho, R., Boff, B., Venkatasamy, A., Tomasetto, C., da Silva Figueiredo Celestino Gomes, P., Rognan, D., Freund, J.-N., Le Lagadec, R., Pfeffer, M., Gross, I., Mellitzer, G., & Gaiddon, C. (2020). Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms. Inorganic Chemistry Frontiers, 7(3), 678–688.
Miller, J. J., Blanchet, A., Orvain, C., Nouchikian, L., Reviriot, Y., Clarke, R. M., Martelino, D., Wilson, D., Gaiddon, C., & Storr, T. (2019). Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chemical Science, 10(46), 10802–10814.
Spaety, M.-E., Gries, A., Badie, A., Venkatasamy, A., Romain, B., Orvain, C., Yanagihara, K., Okamoto, K., Jung, A. C., Mellitzer, G., Pfeffer, S., & Gaiddon, C. (2019). HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers, 11(11), 1747.
Coliat, P., Ramolu, L., Jégu, J., Gaiddon, C., Jung, A. C., & Pencreach, E. (2019). Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC. Cancers, 11(10).
Liang, Y., Hou, L., Li, L., Li, L., Zhu, L., Wang, Y., Huang, X., Hou, Y., Zhu, D., Zou, H., Gu, Y., Weng, X., Wang, Y., Li, Y., Wu, T., Yao, M., Gross, I., Gaiddon, C., Luo, M., … Meng, X. (2019). Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene.
Job, S., Reyniès, A. de, Heller, B., Weiss, A., Guérin, E., Macabre, C., Ledrappier, S., Bour, C., Wasylyk, C., Etienne-Selloum, N., Brino, L., Gaiddon, C., Wasylyk, B., & Jung, A. C. (2019). Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. Cancers, 11(6).
Santoro, A., Vileno, B., Palacios, Ò., Peris-Díaz, M. D., Riegel, G., Gaiddon, C., Krężel, A., & Faller, P. (2019). Reactivity of Cu(ii)-, Zn(ii)- and Fe(ii)-thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation. Metallomics: Integrated Biometal Science, 11(5), 994–1004.
Vidimar, V., Licona, C., Cerón-Camacho, R., Guerin, E., Coliat, P., Venkatasamy, A., Ali, M., Guenot, D., Le Lagadec, R., Jung, A. C., Freund, J.-N., Pfeffer, M., Mellitzer, G., Sava, G., & Gaiddon, C. (2019). A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. Cancer Letters, 440–441, 145–155.
Miller, J. J., Orvain, C., Jozi, S., Clarke, R. M., Smith, J. R., Blanchet, A., Gaiddon, C., Warren, J. J., & Storr, T. (2018). Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer. Chemistry (Weinheim an Der Bergstrasse, Germany), 24(67), 17734–17742.
Lam, N. Y. S., Truong, D., Burmeister, H., Babak, M. V., Holtkamp, H. U., Movassaghi, S., Ayine-Tora, D. M., Zafar, A., Kubanik, M., Oehninger, L., Söhnel, T., Reynisson, J., Jamieson, S. M. F., Gaiddon, C., Ott, I., & Hartinger, C. G. (2018). From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. Inorganic Chemistry, 57(22), 14427–14434.
Minault, Q., Gaiddon, C., Veillon, F., & Venkatasamy, A. (2018). The Champagne sign. Abdominal Radiology (New York), 43(10), 2888–2889.
Chow, M. J., Babak, M. V., Tan, K. W., Cheong, M. C., Pastorin, G., Gaiddon, C., & Ang, W. H. (2018). Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes. Molecular Pharmaceutics, 15(8), 3020–3031.
Gass, B., Marrer, E., Bara, S., Ligier, K., Molinié, F., Colonna, M., Daubisse-Marliac, L., Trétarre, B., Lapôtre-Ledoux, B., Woronoff, A.-S., Guizard, A.-V., Bouvier, V., Troussard, X., Gaiddon, C., Klein, D., Velten, M., & Jégu, J. (2018). Use of a case-mix approach to study the trends in the incidence of second primary cancers. Annals of Epidemiology, 28(5), 322–327.
Babak, M. V., Pfaffeneder-Kmen, M., Meier-Menches, S. M., Legina, M. S., Theiner, S., Licona, C., Orvain, C., Hejl, M., Hanif, M., Jakupec, M. A., Keppler, B. K., Gaiddon, C., & Hartinger, C. G. (2018). Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. Inorganic Chemistry, 57(5), 2851–2864.
Makarchuk, S., Beyer, N., Gaiddon, C., Grange, W., & Hébraud, P. (2018). Holographic Traction Force Microscopy. Scientific Reports, 8(1), 3038.
Manfredelli, S., Delhorme, J.-B., Venkatasamy, A., Gaiddon, C., Brigand, C., Rohr, S., & Romain, B. (2017). Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma? Annals of Surgical Oncology, 24(11), 3324–3330.
Chow, M. J., Alfiean, M., Pastorin, G., Gaiddon, C., & Ang, W. H. (2017). Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies. Chemical Science, 8(5), 3641–3649.
Estrada‐Montaño, A. S., Ryabov, A. D., Gries, A., Gaiddon, C., & Lagadec, R. L. (2017). Iron(III) Pincer Complexes as a Strategy for Anticancer Studies. European Journal of Inorganic Chemistry, 2017(12), 1673–1678.
Licona, C., Spaety, M.-E., Capuozzo, A., Ali, M., Santamaria, R., Armant, O., Delalande, F., Van Dorsselaer, A., Cianferani, S., Spencer, J., Pfeffer, M., Mellitzer, G., & Gaiddon, C. (2017). A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. Oncotarget, 8(2), 2568–2584.
Platet, N., Hinkel, I., Richert, L., Murdamoothoo, D., Moufok-Sadoun, A., Vanier, M., Lavalle, P., Gaiddon, C., Vautier, D., Freund, J.-N., & Gross, I. (2017). The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton. Cancer Letters, 386, 57–64.
Khalil, G., Orvain, C., Fang, L., Barloy, L., Chaumont, A., Gaiddon, C., Henry, M., Kyritsakas, N., & Mobian, P. (2016). Monomeric Ti(iv)-based complexes incorporating luminescent nitrogen ligands: synthesis, structural characterization, emission spectroscopy and cytotoxic activities. Dalton Transactions (Cambridge, England: 2003), 45(47), 19072–19085.
Chow, M. J., Babak, M. V., Wong, D. Y. Q., Pastorin, G., Gaiddon, C., & Ang, W. H. (2016). Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes. Molecular Pharmaceutics, 13(7), 2543–2554.
Chow, M. J., Licona, C., Pastorin, G., Mellitzer, G., Ang, W. H., & Gaiddon, C. (2016). Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance. Chemical Science, 7(7), 4117–4124.
von Grabowiecki, Y., Abreu, P., Blanchard, O., Palamiuc, L., Benosman, S., Mériaux, S., Devignot, V., Gross, I., Mellitzer, G., Gonzalez de Aguilar, J. L., & Gaiddon, C. (2016). Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63. ELife, 5, e10528.
Rico Bautista, H., Saavedra Díaz, R. O., Shen, L. Q., Orvain, C., Gaiddon, C., Le Lagadec, R., & Ryabov, A. D. (2016). Impact of cyclometalated ruthenium(II) complexes on lactate dehydrogenase activity and cytotoxicity in gastric and colon cancer cells. Journal of Inorganic Biochemistry, 163, 28–38.
Tasan, S., Licona, C., Doulain, P.-E., Michelin, C., Gros, C. P., Le Gendre, P., Harvey, P. D., Paul, C., Gaiddon, C., & Bodio, E. (2015). Gold-phosphine-porphyrin as potential metal-based theranostics. Journal of Biological Inorganic Chemistry: JBIC: A Publication of the Society of Biological Inorganic Chemistry, 20(1), 143–154.
von Grabowiecki, Y., Licona, C., Palamiuc, L., Abreu, P., Vidimar, V., Coowar, D., Mellitzer, G., & Gaiddon, C. (2015). Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy. The Journal of Pharmacology and Experimental Therapeutics, 352(1), 23–32.
Chow, M. J., Licona, C., Yuan Qiang Wong, D., Pastorin, G., Gaiddon, C., & Ang, W. H. (2014). Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly. Journal of Medicinal Chemistry, 57(14), 6043–6059.
Klajner, M., Licona, C., Fetzer, L., Hebraud, P., Mellitzer, G., Pfeffer, M., Harlepp, S., & Gaiddon, C. (2014). Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. Inorganic Chemistry, 53(10), 5150–5158.
Boff, B., Gaiddon, C., & Pfeffer, M. (2013). Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes. Inorganic Chemistry, 52(5), 2705–2715.
Vidimar, V., Meng, X., Klajner, M., Licona, C., Fetzer, L., Harlepp, S., Hébraud, P., Sidhoum, M., Sirlin, C., Loeffler, J.-P., Mellitzer, G., Sava, G., Pfeffer, M., & Gaiddon, C. (2012). Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochemical Pharmacology, 84(11), 1428–1436.
Ribeiro, N., Thuaud, F., Bernard, Y., Gaiddon, C., Cresteil, T., Hild, A., Hirsch, E. C., Michel, P. P., Nebigil, C. G., & Désaubry, L. (2012). Flavaglines as potent anticancer and cytoprotective agents. Journal of Medicinal Chemistry, 55(22), 10064–10073.
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012). Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry, 106(1), 90–99.
Benosman, S., Meng, X., Von Grabowiecki, Y., Palamiuc, L., Hritcu, L., Gross, I., Mellitzer, G., Taya, Y., Loeffler, J.-P., & Gaiddon, C. (2011). Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. The Journal of Biological Chemistry, 286(50), 43013–43025.
Fetzer, L., Boff, B., Ali, M., Xiangjun, M., Collin, J.-P., Sirlin, C., Gaiddon, C., & Pfeffer, M. (2011). Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier. Dalton Transactions (Cambridge, England: 2003), 40(35), 8869–8878.
Thuaud, F., Ribeiro, N., Gaiddon, C., Cresteil, T., & Désaubry, L. (2011). Novel flavaglines displaying improved cytotoxicity. Journal of Medicinal Chemistry, 54(1), 411–415.
Klajner, M., Hebraud, P., Sirlin, C., Gaiddon, C., & Harlepp, S. (2010). DNA binding to an anticancer organo-ruthenium complex. The Journal of Physical Chemistry. B, 114(44), 14041–14047.
Meng, X., Leyva, M. L., Jenny, M., Gross, I., Benosman, S., Fricker, B., Harlepp, S., Hébraud, P., Boos, A., Wlosik, P., Bischoff, P., Sirlin, C., Pfeffer, M., Loeffler, J.-P., & Gaiddon, C. (2009). A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP. Cancer Research, 69(13), 5458–5466.
Ohtsubo, C., Shiokawa, D., Kodama, M., Gaiddon, C., Nakagama, H., Jochemsen, A. G., Taya, Y., & Okamoto, K. (2009). Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2. Cancer Science, 100(7), 1291–1299.
Benosman, S., Gross, I., Clarke, N., Jochemsen, A. G., Okamoto, K., Loeffler, J.-P., & Gaiddon, C. (2007). Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis. Cell Death and Differentiation, 14(12), 2047–2057.
Gross, I., Armant, O., Benosman, S., de Aguilar, J. L. G., Freund, J.-N., Kedinger, M., Licht, J. D., Gaiddon, C., & Loeffler, J.-P. (2007). Sprouty2 inhibits BDNF-induced signaling and modulates neuronal differentiation and survival. Cell Death and Differentiation, 14(10), 1802–1812.
Lokshin, M., Li, Y., Gaiddon, C., & Prives, C. (2007). p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Research, 35(1), 340–352.
Gross, I., Lhermitte, B., Domon-Dell, C., Duluc, I., Martin, E., Gaiddon, C., Kedinger, M., & Freund, J.-N. (2005). Phosphorylation of the homeotic tumor suppressor Cdx2 mediates its ubiquitin-dependent proteasome degradation. Oncogene, 24(54), 7955–7963.
Gaiddon, C., Jeannequin, P., Bischoff, P., Pfeffer, M., Sirlin, C., & Loeffler, J. P. (2005). Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms. The Journal of Pharmacology and Experimental Therapeutics, 315(3), 1403–1411.
Di Scala, F., Dupuis, L., Gaiddon, C., De Tapia, M., Jokic, N., Gonzalez de Aguilar, J.-L., Raul, J.-S., Ludes, B., & Loeffler, J.-P. (2005). Tissue specificity and regulation of the N-terminal diversity of reticulon 3. The Biochemical Journal, 385(Pt 1), 125–134.
Gaiddon, C., Lokshin, M., Gross, I., Levasseur, D., Taya, Y., Loeffler, J.-P., & Prives, C. (2003). Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. The Journal of Biological Chemistry, 278(30), 27421–27431.